Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2001 September; 85(7): 944–952.
PMCID: PMC2375096

A prognostic model for ovarian cancer


About 6000 women in the United Kingdom develop ovarian cancer each year and about two-thirds of the women will die from the disease. Establishing the prognosis of a woman with ovarian cancer is an important part of her evaluation and treatment. Prognostic models and indices in ovarian cancer should be developed using large databases and, ideally, with complete information on both prognostic indicators and long-term outcome. We developed a prognostic model using Cox regression and multiple imputation from 1189 primary cases of epithelial ovarian cancer (with median follow-up of 4.6 years). We found that the significant (P≤ 0.05) prognostic factors for overall survival were age at diagnosis, FIGO stage, grade of tumour, histology (mixed mesodermal, clear cell and endometrioid versus serous papillary), the presence or absence of ascites, albumin, alkaline phosphatase, performance status on the ZUBROD-ECOG-WHO scale, and debulking of the tumour. This model is consistent with other models in the ovarian cancer literature; it has better predictive ability and, after simplification and validation, could be used in clinical practice. © 2001 Cancer Research Campaign

Keywords: ovarian cancer, prognostic model, overall survival

Full Text

The Full Text of this article is available as a PDF (98K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, Stock-Novack D, Surwit EA, Malviya VK, Jolles CJ. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 1993 Jan 15;71(2 Suppl):618–627. [PubMed]
  • Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000 Feb 29;19(4):453–473. [PubMed]
  • Ansell SM, Rapoport BL, Falkson G, Raats JI, Moeken CM. Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol. 1993 Aug;50(2):215–220. [PubMed]
  • Brinkhuis M, Baak JP, Meijer GA, van Diest PJ, Mogensen O, Bichel P, Neijt JP. Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma. J Clin Pathol. 1996 Feb;49(2):142–148. [PMC free article] [PubMed]
  • Brun JL, Feyler A, Chêne G, Saurel J, Brun G, Hocké C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol. 2000 Jul;78(1):21–27. [PubMed]
  • Carey MS, Dembo AJ, Simm JE, Fyles AW, Treger T, Bush RS. Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review. Int J Gynecol Cancer. 1993 Jan;3(1):24–35. [PubMed]
  • Dembo AJ, Bush RS, Brown TC. Clinico-pathological correlates in ovarian cancer. Bull Cancer. 1982;69(3):292–297. [PubMed]
  • Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995 Dec 15;142(12):1255–1264. [PubMed]
  • Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996 Feb 28;15(4):361–387. [PubMed]
  • Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994 Jan;12(1):64–69. [PubMed]
  • Högberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol. 1993 Jan;48(1):38–49. [PubMed]
  • Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol. 1999 Nov;106(11):1130–1136. [PubMed]
  • Kappen HJ, Neijt JP. Advanced ovarian cancer. Neural network analysis to predict treatment outcome. Ann Oncol. 1993;4 (Suppl 4):31–34. [PubMed]
  • Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer. 1994 Nov;70(5):1014–1017. [PMC free article] [PubMed]
  • Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994 Jan-Feb;10(1):31–46. [PubMed]
  • Lubsen J, Pool J, van der Does E. A practical device for the application of a diagnostic or prognostic function. Methods Inf Med. 1978 Apr;17(2):127–129. [PubMed]
  • Lund B, Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol. 1991 Apr;2(4):281–287. [PubMed]
  • Lund B, Williamson P, van Houwelingen HC, Neijt JP. Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res. 1990 Aug 1;50(15):4626–4629. [PubMed]
  • Makar AP, Baekelandt M, Tropé CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995 Feb;56(2):175–180. [PubMed]
  • Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi U, Bolis G, Bonazzi C, Colombo N, Epis A, Favalli G, et al. Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer. 1990 Sep;62(3):444–450. [PMC free article] [PubMed]
  • Marx D, Meden H, Brune T, Kron M, Korabiowska M, Kuhn W, Schauer A. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer Res. 1997 Jan-Feb;17(1B):775–780. [PubMed]
  • Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol (Tokyo 1995) 1995 Apr;21(2):167–178. [PubMed]
  • Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995 Aug;86(2):259–264. [PubMed]
  • Peters-Engl C, Obermair A, Heinzl H, Buxbaum P, Sevelda P, Medl M. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999 Oct;81(4):662–666. [PMC free article] [PubMed]
  • Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol. 1985 Feb;65(2):264–270. [PubMed]
  • van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999 Mar 30;18(6):681–694. [PubMed]
  • van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol. 1989 Jun;7(6):769–773. [PubMed]
  • Warwick J, Kehoe S, Earl H, Luesley D, Redman C, Chan KK. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer. 1995 Dec;72(6):1513–1517. [PMC free article] [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK